Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
SL Lowe, BA Willis, A Hawdon… - … Research & Clinical …, 2021 - Wiley Online Library
Introduction This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease.
SL Lowe, BA Willis, A Hawdon, F Natanegara… - … Research & Clinical …, 2021 - go.gale.com
Introduction: This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
SL Lowe, BA Willis, A Hawdon… - … Research & Clinical …, 2021 - search.ebscohost.com
Introduction: This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
SL Lowe, BA Willis, A Hawdon… - … Research & Clinical …, 2021 - search.proquest.com
Methods Patients with AD were enrolled into the single‐ascending dose phase and were
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease
SL Lowe, BA Willis, A Hawdon… - … & dementia (New …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction This study explored the safety and tolerability features of donanemab
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
(LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or …
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
SL Lowe, BA Willis, A Hawdon… - … & Dementia (New …, 2021 - europepmc.org
Methods Patients with AD were enrolled into the single-ascending dose phase and were
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
[HTML][HTML] Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
SL Lowe, BA Willis, A Hawdon… - … Research & Clinical …, 2021 - ncbi.nlm.nih.gov
Methods Patients with AD were enrolled into the single‐ascending dose phase and were
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
SL Lowe, BA Willis, A Hawdon… - … & Dementia (New …, 2021 - europepmc.org
Methods Patients with AD were enrolled into the single-ascending dose phase and were
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …
administered a single, intravenous (IV) dose of donanemab (five dosing cohorts from 0.1 to …